Related Experiment Video
Updated: May 11, 2026
11:58
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Antibody-drug conjugates in hematologic malignancies
1From the Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Summary
Antibody-drug conjugates (ADCs) offer targeted cancer therapy by linking antibodies to toxins. Recent advancements enhance their potential for treating hematologic malignancies like lymphoma and leukemia.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Antibody-drug conjugates (ADCs) combine monoclonal antibodies with cytotoxic payloads for targeted cancer cell destruction.
- ADCs aim to increase therapeutic efficacy against malignant cells while minimizing damage to healthy tissues.
- Historically, ADCs have shown limited success in hematologic malignancies, necessitating further development.
Purpose of the Study:
- To review select Antibody-drug conjugates (ADCs) in development for hematologic malignancies.
- To highlight recent advancements improving the clinical value of ADCs.
- To discuss the future potential applications of ADC technology in cancer treatment.
Main Methods:
- Review of preclinical models and early-phase clinical trials of ADCs.
- Analysis of advancements in ADC linkage technology and cytotoxin selection.
- Discussion of novel ADC formats, including smaller conjugates.
Main Results:
- Recent technological improvements have significantly enhanced the clinical potential of ADCs.
- ADCs demonstrate promise in targeting specific surface antigens on cancer cells.
- Several ADCs are in various stages of development for lymphoma, multiple myeloma, and leukemia.
Conclusions:
- Advancements in ADC technology have overcome previous limitations, improving efficacy and safety.
- ADCs represent a promising therapeutic strategy for hematologic malignancies.
- Future applications may include restoring tumor suppressor activity and targeting the tumor microenvironment.
Related Concept Videos
01:01Hypersensitivity Reactions: Cytolytic Reactions
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:26Antibody Actions
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...